Why overall survival and not progression free survival improves in era of program death inhibitors.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 5, p. 398, doi. 10.1177/1078155217712402
- By:
- Publication type:
- Article
Works matching IS 10781552 AND DT 2018 AND VI 24 AND IP 5
Results: 14
1
2
Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 5, p. 379, doi. 10.1177/1078155217712401
- By:
- Publication type:
- Article
3
Interdisciplinary implementation of tacrolimus intravenous standard concentration in hematopoietic stem cell transplantation recipients.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 5, p. 365, doi. 10.1177/1078155217710552
- By:
- Publication type:
- Article
4
Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 5, p. 393, doi. 10.1177/1078155217710714
- By:
- Publication type:
- Article
5
The impact of pharmacist telephone calls after discharge on satisfaction of oncology patients: A randomized controlled study.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 5, p. 359, doi. 10.1177/1078155217709616
- By:
- Publication type:
- Article
6
Impact of a specialty pharmacy case management service on adherence in patients receiving oral antineoplastic agents.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 5, p. 371, doi. 10.1177/1078155217708022
- By:
- Publication type:
- Article
7
Prediction of cardiovascular risk in cancer patients of South India using WHO/ISH risk prediction charts and Framingham score – A prospective study.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 5, p. 354, doi. 10.1177/1078155217707334
- By:
- Publication type:
- Article
8
Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 5, p. 348, doi. 10.1177/1078155217704989
- By:
- Publication type:
- Article
9
Impact of an integrated oral chemotherapy program on patient adherence.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 5, p. 332, doi. 10.1177/1078155217703792
- By:
- Publication type:
- Article
10
Feasibility of extended dosing intervals of denosumab.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 5, p. 343, doi. 10.1177/1078155217703791
- By:
- Publication type:
- Article
11
Assessing the need for improved strategies and medication-related education to increase adherence for oral anticancer medications in the young adult oncology population.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 5, p. 337, doi. 10.1177/1078155217703790
- By:
- Publication type:
- Article
12
Recommendation or refusal but why not quality of surgery?
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 5, p. 398, doi. 10.1177/1078155217701297
- By:
- Publication type:
- Article
13
Could knee inflammatory synovitis be induced by pembrolizumab?
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 5, p. 389, doi. 10.1177/1078155217701292
- By:
- Publication type:
- Article
14
Incidence of late onset neutropenia associated with rituximab use in B cell lymphoma patients undergoing autologous stem cell transplantation.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 5, p. 323, doi. 10.1177/1078155217702214
- By:
- Publication type:
- Article